Introduction

Oral lichen planus (OLP) represents one of the most common chronic autoimmune diseases affecting the oral mucosa, affecting approximately 0.5-2% of the population globally with considerable geographic variation. The condition manifests as a chronic, T-cell-mediated immune-inflammatory disease characterized by lymphocytic infiltration of the oral epithelium producing variable clinical presentations ranging from asymptomatic reticular (lacy) white patterns to symptomatic erosive disease with significant pain, bleeding, and functional impairment.

The pathogenesis of oral lichen planus involves aberrant T-cell-mediated immune responses producing cytotoxic attack against basal keratinocytes, resulting in a characteristic saw-tooth epithelial-connective tissue interface and dense lymphocytic infiltrate. While the precise etiology remains incompletely understood, associations with hepatitis C virus in some populations, drug-induced lichenoid reactions, and potential genetic predisposition suggest multifactorial disease mechanisms. Approximately 0.5-5% of OLP cases demonstrate malignant transformation to oral squamous cell carcinoma, necessitating systematic surveillance and dysplasia monitoring.

This comprehensive review examines the pathobiology of oral lichen planus, clinical presentation patterns, diagnostic criteria, malignancy risk assessment, and evidence-based management strategies enabling symptom control and long-term disease monitoring.

Pathogenesis and Immunological Mechanisms

Oral lichen planus represents a T-cell-mediated autoimmune disease involving aberrant immune recognition of oral epithelial antigens triggering cytotoxic responses against basal keratinocytes. The disease typically involves CD8+ (cytotoxic) T-lymphocytes with smaller populations of CD4+ (helper) T-cells. These lymphocytes accumulate in the oral lamina propria immediately beneath the epithelium, producing basement zone destruction and basal cell liquefactive degeneration.

The target antigens driving immune attack remain incompletely defined. Potential antigens include modified epithelial self-antigens created through viral infection or chemical modification, viral antigens (particularly hepatitis C virus in HCV-seropositive cases), or dyskeratotic cell remnants triggering immune recognition. Molecular mimicry mechanisms may enable infections (hepatitis C virus, other chronic viral infections) to trigger cross-reactive T-cell responses against epithelial antigens, perpetuating disease even after initial viral infection clearance.

Genetic predisposition likely plays a role, with certain human leukocyte antigen (HLA) alleles (particularly HLA-DR3 and HLA-DQ2) showing disease association in some populations. Systemic factors including chronic stress, hormonal influences, and systemic immunosuppression can modulate disease manifestation and severity. The chronic, relapsing nature of OLP suggests failure of immune regulation mechanisms enabling perpetual T-cell activation and epithelial damage.

Clinical Presentation and Diagnostic Criteria

Oral lichen planus presents in multiple clinical forms, with considerable variation in appearance and symptomatology. The reticular (lacy) form appears most commonly, presenting as a characteristic white network pattern creating lace-like appearance against normal-colored oral mucosa. These white lines (Wickham striae) represent hyperkeratosis and acanthosis produced by the underlying immune inflammation. Reticular OLP is typically asymptomatic or minimally symptomatic, often discovered incidentally during routine dental examination.

The erosive form presents as painful ulcerations with erythematous bases bordered by white keratotic margins. Erosions may be extensive, producing significant bleeding, impaired oral intake, and functional limitation. Erosive OLP often causes substantial patient distress and warrants more aggressive management. The erosive form demonstrates greater dysplasia risk and higher malignancy transformation rates compared to reticular disease.

The plaque form demonstrates thickened white patches resembling oral leukoplakia, creating diagnostic confusion. Distinction between OLP and oral leukoplakia depends on histopathological findings and immunofluorescence patterns.

The bullous form manifests as fluid-filled vesicles or bullae that rupture producing ulcerations. This presentation is relatively uncommon but produces severe symptoms and potential dehydration from fluid loss.

The atrophic form presents with erythematous patches lacking white striations, representing extensive epithelial atrophy with loss of normal surface keratinization. This form frequently produces pain and bleeding.

OLP typically affects buccal mucosa, attached gingiva, dorsum and lateral borders of tongue, and hard palate. Gingival involvement may produce desquamative gingivitis (painful gingival erosions with erythema extending beyond true pocket margins). Anterior teeth attachment margins often demonstrate characteristic linear erythema.

Diagnostic criteria established by the World Health Organization and International Classification of Diseases require:

  • Bilateral, interlacing white striae or patterns
  • Absence of superficial ulceration or erosive form OR erosions with reticular pattern peripherally
  • Oral lichen planus-consistent histopathology
  • Direct immunofluorescence demonstrating fibrinogen deposition along the epithelial-connective tissue interface (linear IgA pattern in true OLP; other patterns suggesting drug-induced lichenoid reaction or systemic lupus erythematosus)

Histopathological Features and Dysplasia Assessment

Histopathological examination confirms oral lichen planus diagnosis and enables dysplasia assessment critical for malignancy risk determination. Characteristic findings include:

Epithelial changes: Hyperkeratosis (thickened keratinized layer), acanthosis (epithelial thickening), and saw-tooth epithelial-connective tissue interface with pointed epithelial rete processes creating the characteristic saw-tooth pattern. Inflammatory infiltrate: Dense band-like lymphocytic infiltration of the lamina propria, predominantly consisting of CD8+ T-lymphocytes concentrated immediately beneath the epithelium. Basal zone changes: Liquefactive (colliquative) degeneration of basal keratinocytes producing loss of epithelial-connective tissue interface integrity and potential ulceration.

Dysplasia assessment in oral lichen planus follows similar WHO guidelines as other oral mucosa lesions. However, dysplasia in OLP may be related to chronic inflammation rather than malignant transformation potential in some cases, complicating management decisions. Approximately 0.5-5% of OLP cases demonstrate malignant transformation to oral squamous cell carcinoma over long-term follow-up (10-20+ years), with transformation risk correlating with erosive disease, severe dysplasia grade, and duration of disease.

Direct immunofluorescence demonstrates fibrinogen deposition at the epithelial-connective tissue interface (linear IgA pattern), distinguishing true OLP from drug-induced lichenoid reactions (which typically show IgM, IgG deposition) or systemic lupus erythematosus (which shows immune complex deposition at the epithelial basement membrane and superficial perivascular areas).

Malignancy Risk and Dysplasia Monitoring

Malignant transformation in oral lichen planus represents a critical clinical concern requiring systematic monitoring. Transformation rates vary considerably in reported series (0.5-5% overall), with higher rates observed in erosive disease (5-20%) compared to reticular disease (less than 1%). Geographic variation in transformation rates may reflect HCV prevalence differences, surveillance intensity, and population characteristics.

Risk factors for malignant transformation include:

  • Erosive disease form (substantially higher transformation risk)
  • Severe dysplasia on biopsy
  • Long disease duration
  • Presence of hepatitis C virus (in HCV-endemic regions)
  • Possible role of smoking and alcohol exposure (though less established than in squamous cell carcinoma generally)

Systematic dysplasia monitoring requires periodic biopsy and histopathological examination. Most authorities recommend biopsy at initial diagnosis to establish baseline dysplasia status, repeat biopsy at 1-2 years and then every 3 years if stable, or more frequently if clinical changes develop (enlargement, increasing erythema, ulceration, development of nodularity). Lesions showing dysplasia progression warrant consideration of more aggressive intervention.

Drug-Induced Lichenoid Reactions

Drug-induced lichenoid oral reactions clinically resemble OLP but represent hypersensitivity reactions to medications rather than true autoimmune disease. Medications associated with lichenoid reactions include:

  • NSAIDs (aspirin, ibuprofen, naproxen)
  • Antihypertensives (methyldopa, captopril, labetalol)
  • Antimalarials (hydroxychloroquine)
  • Antibiotics (tetracyclines, penicillins)
  • Antihistamines
  • Phenothiazines
  • Gold salts
  • Chemotherapy agents

Distinguishing drug-induced lichenoid reactions from true OLP relies on immunofluorescence findings (IgM or IgG deposition versus fibrinogen), temporal correlation with medication initiation, and potential resolution following medication discontinuation. Direct immunofluorescence represents the most reliable distinguishing feature.

Management Strategies and Treatment Protocols

Topical corticosteroid therapy: First-line treatment for symptomatic OLP involves topical corticosteroid application, often combined with oral hygiene optimization and dietary modifications (avoiding spicy, acidic, hot foods). High-potency topical corticosteroids (fluocinonide 0.05%, triamcinolone 0.1%) applied 2-3 times daily typically control symptoms within days. Intralesional corticosteroid injection (triamcinolone acetonide 40 mg/mL) enables high local drug concentration with minimal systemic absorption, particularly useful for localized severe erosions. Systemic corticosteroid therapy: Severe, widespread OLP not responding to topical therapy may require systemic corticosteroids (prednisolone 20-40 mg daily, gradually tapered over 2-4 weeks as symptoms improve). Systemic corticosteroids produce rapid symptom resolution but require careful tapering to avoid disease flare upon discontinuation. Retinoids: Topical or systemic retinoid (tretinoin, isotretinoin, acitretin) therapy shows efficacy in some cases, particularly erosive disease. Mechanism may involve modulation of epithelial differentiation and immune response. Treatment duration typically extends 2-3 months. Systemic retinoids require pregnancy prevention in reproductive-aged women due to severe teratogenic potential. Calcineurin inhibitors: Topical tacrolimus or pimecrolimus applied 2-3 times daily show efficacy comparable to topical corticosteroids, particularly valuable when prolonged corticosteroid use carries adverse effects risk. Systemic tacrolimus can be employed for severe refractory disease. Immunosuppressive therapy: Severe, corticosteroid-refractory OLP may require immunosuppressive agents including:
  • Azathioprine (1-2 mg/kg/day)
  • Mycophenolate mofetil (1-3 grams/day)
  • Cyclosporine
  • Methotrexate
These agents suppress overall immune function, increasing infection risk and requiring systematic monitoring. Biologic therapies: TNF-α inhibitors (adalimumab, infliximab) and other biologic immunomodulators show promise for severe, refractory OLP in case reports and small series, though randomized controlled trial evidence remains limited. Supportive care: All patients benefit from excellent oral hygiene using soft toothbrushes and gentle technique, dietary modification avoiding irritating foods, and regular professional monitoring. Water-based mouth rinses rather than alcohol-containing rinses prevent tissue irritation.

Patient Monitoring and Surveillance Protocols

Following initial diagnosis, systematic surveillance enables early detection of dysplasia progression or malignant transformation. Recommended monitoring intervals include:

  • Initial examination and biopsy to establish diagnosis and baseline dysplasia status
  • Clinical evaluation every 1-2 months initially, then every 3-6 months with stable disease
  • Repeat biopsy at 1-2 years, then every 3 years if dysplasia-free
  • More frequent monitoring (every 1-2 months) for erosive disease
  • Expedited biopsy if clinical changes develop

Hepatitis C Virus Association

In hepatitis C virus-endemic regions (Mediterranean, Asia, Latin America), strong associations exist between oral lichen planus and HCV seroprevalence. The prevalence of HCV among OLP patients in HCV-endemic regions reaches 50-60%, compared to 0-10% in non-endemic regions. The mechanism likely involves molecular mimicry enabling HCV-specific immune responses to cross-react with epithelial antigens. HCV-positive OLP may demonstrate distinct clinical and transformation characteristics, though evidence remains incomplete.

Psychosocial Considerations

OLP significantly impacts quality of life in symptomatic patients. Chronic pain, oral dysfunction, impaired taste, dietary limitations, and psychological stress from chronic disease burden frequently produce anxiety and depression. Multidisciplinary management including oral health providers, psychologists, and oral surgeons when necessary optimizes outcomes and patient well-being.

Conclusion

Oral lichen planus represents a chronic T-cell-mediated autoimmune disease requiring systematic diagnosis confirmation, dysplasia assessment, and appropriate management for symptom control. Topical and systemic corticosteroid therapy represents first-line treatment, with alternative agents employed for refractory disease or those intolerant of corticosteroids. Systematic surveillance with periodic biopsy and dysplasia assessment enables early detection of malignant transformation, improving prognosis through early intervention. Distinction from drug-induced lichenoid reactions and assessment for hepatitis C virus association guides comprehensive patient management. Multidisciplinary approaches addressing oral health, systemic disease, psychosocial factors, and quality-of-life impacts provide optimal patient outcomes in this chronic disease.